The effects of DNA methylation and epigenetic factors on the expression of CD133 in ovarian cancers

Journal of Ovarian Research

Jae-Kwan Lee¹  Jin-Hwa Hong¹  Yung-Taek Ouh¹  Kyeong A So¹  Kyung-Jin Min¹ 

[1] Department of Obstetrics and Gynecology, Guro Hospital, College of Medicine, Korea University, Seoul, Korea

关键词: Trichostatin A;    5`-aza-2`-deoxycytidine;    Epigenetics;    CD133;    Cancer stem cell;   

Others  :  814949
DOI  :  10.1186/1757-2215-5-28

 received in 2012-09-07, accepted in 2012-10-03,  发布年份 2012

【 摘 要 】

Background

To identifying the effects of DNA methylation and epigenetic factors on the expression of CD133, a cancer stem cell marker, in gynecologic cancer cell lines.

Methods

Ovarian cancer cell lines (OVCAR-8 and IGROV-1) and an endometrial cancer cell line (Ishikawa) were treated with 5-aza-2`-deoxycytidine (DAC) or Trichostatin A (TSA). Expression of CD133 was evaluated by quantitative real-time PCR, methylation-specific PCR (MSP), reverse transcription-PCR, western blot, and FACS analysis. All results are representative of three independent experiments.

Results

CD133 mRNA expression varied among the different cell lines; the weakest expression was observed in OVCAR-8 cells, while it was strongly expressed in Ishikawa cells. The degree of methylation of the CD133 P2 promoter was 61% in OVCAR-8 cells, 53% in IGROV-1 cells, and 43% in Ishikawa cells. CD133 expression was increased at both the mRNA and protein level after DAC treatment. On the contrary, CD133 mRNA expression decreased after TSA treatment decreased in all cell lines except OVCAR-8. In addition, MSP of the CD133 P2 promoter revealed that methylation was reduced after treatment with either DAC or TSA.

Conclusions

The expression of the CD133 antigen in primary ovarian and endometrial cancer cell lines is regulated by epigenetics, as indicated by its increased expression following DAC treatment and irregular expression pattern followed by TSA treatment. In addition, the expression of CD133 was negatively correlated with the degree of methylation of the CD133 P2 promoter.

【 授权许可】

   
2012 Min et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1 .

Figure 2 .

Figure 3 .

Figure 4 .

Figure 5 .

Figure 6 .

Figure 7 .

【 参考文献 】

• [1]Howlader N, Noone A, Krapcho M, Neyman N, Aminou R, Waldron W, Altekruse S, Kosary C, Ruhl J, Tatalovich Z, et al.: SEER Cancer Statistics Review, 1975–2008. National Cancer Institute, Bethesda, MD; 2011.
• [2]Barton CA, Clark SJ, Hacker NF, O'Brien PM: Epigenetic markers of ovarian cancer. Adv Exp Med Biol 2008, 622:35-51.
• [3]Bomken S, Fiser K, Heidenreich O, Vormoor J: Understanding the cancer stem cell. Br J Cancer 2010, 103:439-445.
• [4]You H, Ding W, Rountree CB: Epigenetic regulation of cancer stem cell marker CD133 by transforming growth factor-beta. Hepatology 2010, 51:1635-1644.
• [5]Ki KD, Lee SK, Tong SY, Lee JM, Song DH, Chi SG: Role of 5'-CpG island hypermethylation of the FHIT gene in cervical carcinoma. J Gynecol Oncol 2008, 19:117-122.
• [6]Friel AM, Zhang L, Curley MD, Therrien VA, Sergent PA, Belden SE, Borger DR, Mohapatra G, Zukerberg LR, Foster R, Rueda BR: Epigenetic regulation of CD133 and tumorigenicity of CD133 positive and negative endometrial cancer cells. Reprod Biol Endocrinol 2010, 8:147. BioMed Central Full Text
• [7]Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M: Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer. Hum Pathol 2010, 41:1516-1529.
• [8]Rutella S, Bonanno G, Procoli A, Mariotti A, Corallo M, Prisco MG, Eramo A, Napoletano C, Gallo D, Perillo A, et al.: Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors. Clin Cancer Res 2009, 15:4299-4311.
• [9]Fong MY, Kakar SS: The role of cancer stem cells and the side population in epithelial ovarian cancer. Histol Histopathol 2010, 25:113-120.
• [10]Ahmed N, Abubaker K, Findlay J, Quinn M: Epithelial mesenchymal transition and cancer stem cell-like phenotypes facilitate chemoresistance in recurrent ovarian cancer. Curr Cancer Drug Targets 2010, 10:268-278.
• [11]Esteller M: The necessity of a human epigenome project. Carcinogenesis 2006, 27:1121-1125.
• [12]Pleshkan VV, Vinogradova TV, Sverdlov ED: Methylation of the prominin 1 TATA-less main promoters and tissue specificity of their transcript content. Biochim Biophys Acta 2008, 1779:599-605.
• [13]Ponnusamy MP, Batra SK: Ovarian cancer: emerging concept on cancer stem cells. J Ovarian Res 2008, 1:4. BioMed Central Full Text
• [14]Shmelkov SV, St Clair R, Lyden D, Rafii S: AC133/CD133/Prominin-1. Int J Biochem Cell Biol 2005, 37:715-719.
• [15]Jeon YK, Kim SH, Choi SH, Kim KH, Yoo BC, Ku JL, Park JG: Promoter hypermethylation and loss of CD133 gene expression in colorectal cancers. World J Gastroenterol 2010, 16:3153-3160.
• [16]Yi JM, Tsai HC, Glockner SC, Lin S, Ohm JE, Easwaran H, James CD, Costello JF, Riggins G, Eberhart CG, et al.: Abnormal DNA methylation of CD133 in colorectal and glioblastoma tumors. Cancer Res 2008, 68:8094-8103.
• [17]Song W, Li H, Tao K, Li R, Song Z, Zhao Q, Zhang F, Dou K: Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma. Int J Clin Pract 2008, 62:1212-1218.
• [18]Zhang J, Guo X, Chang DY, Rosen DG, Mercado-Uribe I, Liu J: CD133 expression associated with poor prognosis in ovarian cancer. Mod Pathol 2012, 25:456-464.
• [19]Ferrandina G, Martinelli E, Petrillo M, Prisco MG, Zannoni G, Sioletic S, Scambia G: CD133 antigen expression in ovarian cancer. BMC Cancer 2009, 9:221. BioMed Central Full Text
• [20]Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, et al.: Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009, 28:209-218.
• [21]Shmelkov SV, Jun L, St Clair R, McGarrigle D, Derderian CA, Usenko JK, Costa C, Zhang F, Guo X, Rafii S: Alternative promoters regulate transcription of the gene that encodes stem cell surface protein AC133. Blood 2004, 103:2055-2061.
• [22]Shankar S, Srivastava RK: Histone deacetylase inhibitors: mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008, 615:261-298.